ARDX241101P10000
- 0.00
- 0.000.00%
Ardelyx Newsroom
Here Are the Major Earnings After the Close Today
Ardelyx's Earnings Outlook
Ardelyx Presents Results From Its IBS in America 2024 Supplemental Survey at the American College of Gastroenterology's (ACG) Annual Meeting
Earnings Preview: Ardelyx to Report Financial Results Post-market on October 31
Earnings Preview: Ardelyx (ARDX) Q3 Earnings Expected to Decline
Ardelyx Announces Launch of Gut Matters: Discoveries and Innovations, a New Podcast for the IBS-C Patient Community
Express News | Ardelyx Announces the Derek Forfang Patient Advocate Award to Recognize Advocates for the Chronic Kidney Disease Community
Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024
Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH (Tenapanor) for Adults With Chronic Kidney Disease on Dialysis at the American Society of Nephrology's Kidney Week
Even Though Ardelyx (NASDAQ:ARDX) Has Lost US$210m Market Cap in Last 7 Days, Shareholders Are Still up 352% Over 3 Years
Ardelyx Announces Publication of a Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental Gastroenterology
Wall Street Analysts Think Ardelyx (ARDX) Could Surge 65.4%: Read This Before Placing a Bet
Piper Sandler Maintains Ardelyx(ARDX.US) With Hold Rating, Maintains Target Price $7
Piper Sandler Remains a Hold on Ardelyx (ARDX)
Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?
Market Sentiment Around Loss-Making Ardelyx, Inc. (NASDAQ:ARDX)
High Growth Tech Stocks In The United States You Should Know
Ardelyx to Participate at the 2024 Cantor Global Healthcare Conference
Analysts Offer Insights on Healthcare Companies: Nuvalent (NUVL) and Ardelyx (ARDX)
With 62% Ownership, Ardelyx, Inc. (NASDAQ:ARDX) Boasts of Strong Institutional Backing